Maximize Repertoire Diversity. Shorten Your Timelines.
At Twist Biopharma Solutions, your antibody discovery campaigns are driven by experienced scientists on industry-leading in vivo platforms. From our proprietary DiversimAb hyperimmune mouse to camelids for VHH discovery, our team partners with you to design immunization strategies and customize campaigns to ensure the desired molecular profile for even the most difficult targets. Exploit the untapped immune repertories to discover high affinity and functional antibodies by leveraging Twist's comprehensive in vivo discovery portfolio.
Antibody Discovery Powered by the
Best-in-Class Technologies
Rapid and Predictable Immunization to Antibody Sequence Timelines
The hyperimmune response of the DiversimAb mouse can generate appropriate titers in as little as three weeks, enabling rapid antibody discovery. Twist’s B-cell screening on the Beacon platform and the optimized Hybridoma development workflow enables the high-throughput discovery of large, diverse sets of antibodies on a timeline unimaginable a few years ago. Days after tissue collection, the Beacon provides a rich data set about each antibody screened to identify the rare, active, cross-reactive mAbs and VHH antibodies ideal for clinical development.
Find the Ideal Antibody for Your Application
Our suite of high-throughput screening and characterization platforms allows us to identify ideal binders and screen for high-affinity and functionally relevant antibodies early in the discovery process. With our advanced instrumentation suite, we can rapidly characterize leads by ELISA, on-cell screening, antibody kinetics analysis, and epitope binning across all discovery projects.
Experience Freedom from Royalties and Milestones
As of today, your in vivo discovery campaigns have no royalty or milestone burdens We offer flexible project terms, including a fee-for-service option, to accommodate different partners, giving you the most cost-effective, flexible, and de-risked collaboration and path to explore the potential of your lead candidates
What Scientists Have to Say
Twist is the only synthetic DNA provider who can deliver the quantity and quality of DNA we need for our projects rapidly. We are working with them not only as a vendor for synthetic genes and antibodies, but have expanded our relationship to leverage the Twist Biopharma capabilities, which we believe complement our antibody discovery efforts.”
ROBERT CARNAHAN, PHD
Associate Director of the Vanderbilt Vaccine Center
Our platform rapidly generates and validates new targets for treating challenging cancers. Working with Abveris will enable us to quickly identify and select highly specific antibodies for those targets, so that we can take the best antibody forward to address the needs of particular patient populations.”
JEFF GOLDBERG, CEO
Immunitas Therapeutics
Explore More
Writing the Future of Biologics to Discover and Optimize Antibodies
Get in Touch With Us
Antibody enthusiasts are standing by and would love to hear more about your discovery needs. Challenging targets welcome!
